Acuta Capital Partners LLC Cuts Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Acuta Capital Partners LLC trimmed its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 9.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,118,992 shares of the company's stock after selling 211,945 shares during the period. Taysha Gene Therapies makes up approximately 3.4% of Acuta Capital Partners LLC's investment portfolio, making the stock its 10th largest position. Acuta Capital Partners LLC owned about 1.03% of Taysha Gene Therapies worth $4,259,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Creative Planning acquired a new stake in Taysha Gene Therapies in the third quarter valued at about $28,000. Principal Financial Group Inc. acquired a new stake in shares of Taysha Gene Therapies in the 2nd quarter valued at approximately $48,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Taysha Gene Therapies by 79.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company's stock valued at $79,000 after purchasing an additional 17,446 shares during the last quarter. Intech Investment Management LLC bought a new position in Taysha Gene Therapies in the 3rd quarter valued at approximately $85,000. Finally, Scientech Research LLC acquired a new stake in Taysha Gene Therapies in the second quarter valued at approximately $97,000. 77.70% of the stock is owned by institutional investors.

Taysha Gene Therapies Trading Up 2.4 %

NASDAQ TSHA traded up $0.07 during mid-day trading on Thursday, reaching $3.00. 4,802,974 shares of the stock were exchanged, compared to its average volume of 2,779,427. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The stock has a market cap of $614.83 million, a P/E ratio of 4.76 and a beta of 0.44. The stock has a 50 day simple moving average of $2.02 and a 200-day simple moving average of $2.38. Taysha Gene Therapies, Inc. has a one year low of $1.19 and a one year high of $4.32.

Wall Street Analyst Weigh In

TSHA has been the topic of a number of research reports. Cantor Fitzgerald restated an "overweight" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Canaccord Genuity Group upped their price objective on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a "buy" rating in a research note on Friday, November 15th. Chardan Capital reiterated a "buy" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. Needham & Company LLC reissued a "buy" rating and set a $6.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $5.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $6.63.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.